 First Patient Dosed in Validive Phase 2b3 VOICE Clinical Trial Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021 Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery 